Abstract
Objective/Background:
Robotic-assisted minimally invasive esophagectomy (RAMIE) has significantly improved the quality of surgery, reflecting in better functional outcomes, faster recovery, less postoperative morbidity, and even improved oncological results in patients with locally advanced cancer of the esophagus compared with an open approach.
Methods:
The IDEAL (idea, development, exploration, assessment, long-term study) Framework provides a structured, staged approach to evaluating surgical innovations.
Results:
The Stage 1 studies describe the introduction of this technique published in 2003 and 2006 (Horgan et al, van Hillegersberg et al) as a proof of concept already showing an acceptable benchmarking for early implementation (48% pulmonary complication rate, 5% mortality). The Stage 2 Exploration phase followed, showing oncological long-term follow-up with 48% 5-year survival rates. The Stage 3 trials (ie, ROBOT Trial) have proven RAMIE to not only be equivalent, but significantly superior for overall complications, pain scores, and quality of life compared with an open approach. Long-term follow-up revealed no differences in survival, making RAMIE oncologically equivalent at a minimum. The Stage 4 evaluation phase started in 2017 with the foundation of the Upper GI International Robotic Association (UGIRA) global registry, which as of November 2025 has 58 contributing sites worldwide and collected 5567 RAMIE cases. With textbook outcome of 41-61%, contemporary leak rates of 11-16% in the most recent UGIRA cohort depending on technique and mortality
Conclusion:
The foundation of the international UGIRA registry has provided compelling evidence regarding standardized training pathways and guidelines and already serves as a scientific template for future technical evolution in upper GI surgery.